Renizgamglogene autogedtemcel is under clinical development by Editas Medicine and currently in Phase III for Sickle Cell Disease. According to GlobalData, Phase III drugs for Sickle Cell Disease have a 47% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Renizgamglogene autogedtemcel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Renizgamglogene autogedtemcel overview
EDIT-301 (renizgamglogene autogedtemcel) is under development for the treatment of beta-thalassemia and sickle cell disease. It is developed based on CRISPR/Cas12a genome editing technology. It is administered through intravenous route. The therapeutic candidate constitutes patient derived CD34 positive hematopoietic stem and progenitor cells edited at the gamma globin gene (HBG1 and HBG2) promoters.
Editas Medicine overview
Editas Medicine, formerly Gengine, is a clinical stage biotechnology company focused on the development of genome treatments for rare diseases. The company is developing a proprietary genome editing platform based on its in-licensed clustered regularly interspaced short palindromic repeats (CRISPR) technology. The company’s pre-clinical pipeline spans investigational candidates for the treatment of ocular and blood diseases, cancer, and diseases of other organs and tissues. Its pipeline of medicines is focusing for people living with serious diseases. The company works in collaboration with Allergan/ AbbVie Inc, BlueRock Therapeutics, AskBio, Bayer AG, The Broad Institute Inc, Massachusetts Institute of Technology, and others to discover and develop its pipeline products. Editas Medicine is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of Renizgamglogene autogedtemcel’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
